{"analyses":[{"ciPctValue":"95","groupDescription":"With 176 evaluable participants per treatment arm, there would have been \\>=80% power to detect a difference across two treatment arms of 33% of the standard deviation in average hemoglobin levels through two-sided alternative, with a 2.5% type I error rate.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1124","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false},{"ciPctValue":"95","groupDescription":"With 176 evaluable participants per treatment arm, there would have been \\>=80% power to detect a difference across two treatment arms of 33% of the standard deviation in average hemoglobin levels through two-sided alternative, with a 2.5% type I error rate.","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2051","statisticalMethod":"t-test, 2 sided","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.46","value":"2.1"},{"groupId":"OG001","spread":"1.61","value":"2.0"},{"groupId":"OG002","spread":"1.64","value":"1.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"163"}],"units":"Participants"}],"description":"Value at 16 weeks minus value at baseline.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.","id":"OG000","title":"DA + IV Iron"},{"description":"Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.","id":"OG001","title":"DA + Oral Iron"},{"description":"Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.","id":"OG002","title":"DA + Placebo"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Baseline and 16 weeks","title":"Mean Increment in Hemoglobin Level at Week 16","type":"SECONDARY","unitOfMeasure":"g/dL"}